Navigation Links
Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
Date:9/1/2008

MUNICH, Germany, Sept. 2 /PRNewswire-FirstCall/ -- Data presented today at the Annual Congress of the European Society of Cardiology showed that the investigational oral Factor Xa inhibitor DU-176b reduced the incidence of venous thromboembolism (VTE) compared with dalteparin among patients undergoing elective unilateral hip replacement surgery. There was a statistically significant dose response in efficacy (P <0.01), and the observed bleeding rates were low across the groups. DU-176b is being developed solely by Daiichi Sankyo Company, Limited (TSE: 4568) and the data were presented by lead investigator Dr. Gary Raskob.

This randomized, double-blind comparative study examined the safety and efficacy of four doses of DU-176b (15, 30, 60 and 90 mg once daily) versus the low molecular weight heparin, dalteparin. The study was conducted among 903 patients in Europe and North America undergoing total hip replacement surgery.

"These findings are encouraging and we look forward to further study on this Factor Xa inhibitor," said Gary Raskob, Ph.D., Dean, College of Public Health at the University of Oklahoma Health Sciences Center. "These findings indicate DU-176b may provide a high degree of efficacy, but further study is needed."

"As the company that discovered one of the first Factor Xa small molecules (DX-9065a), we are proud to be building on our innovation in cardiovascular disease and tackling the need for better and more effective ways to prevent thrombosis," said John Alexander M.D., president, Daiichi Sankyo Pharma Development. "We expect to commence phase III studies for DU-176b, targeting patients with atrial fibrillation, before the end of 2008.

Study Result Details

VTE incidence (%) Bleeding occurrence*** (%)

Dalteparin 43.8 [35.5-52.3]# 0 [0-2.1]

DU-176b 15mg 28.2 [21.6-35.6]* 1.6 [0.3-4.5]

30mg 21.2 [15.0-28.6]** 1.8 [0.4-5.1]

60mg 15.2 [10.0-21.8]** 2.2 [0.6-5.4]

90mg 10.6 [6.2-16.6]** 2.3 [0.6-5.7]

#95% confidence interval, * p=0.005, **p<0.001, ***Major+Clinically

Relevant

About DU-176b

DU-176b is an oral anticoagulant that directly inhibits Factor Xa, a clotting factor in the blood. Daiichi Sankyo is developing DU-176b as a potential new treatment for the prevention of both arterial and venous thromboembolism.

About Daiichi Sankyo

A global pharmaceutical innovator, Daiichi Sankyo Co., Ltd., headed by President Takashi Shoda was established in 2005 through the merger of two leading Japanese pharmaceutical companies, Daiichi Pharmaceutical Co., Ltd. and Sankyo Co., Ltd. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research and development is cardiometabolic diseases, including therapies for thrombosis, dyslipidemia, hypertension, diabetes, and acute coronary syndromes. Equally important to the company is the discovery of new medicines in the areas of infectious diseases, cancer, bone and joint diseases, and immune disorders. For more information, visit http://www.daiichisankyo.com.


'/>"/>
SOURCE Daiichi Sankyo
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
3. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
4. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... -- Research and Markets has announced the addition of the ... their offering. ... separate comprehensive analytics for the US, Canada , ... , and Rest of World. Annual estimates and forecasts are provided ... provided for these markets. Market data and analytics are derived from primary ...
(Date:2/17/2017)... Feb. 17, 2017  Featuring new ... at the  2017 HIMSS Conference & Exhibition (HIMSS17 ),  ... a global leader in health ... of population health management, acute healthcare ... integrated in a highly secure, cloud-based ...
(Date:2/16/2017)... , Feb. 16, 2017 Research and ... for Emerging Medical Device Technologies" report to their offering. ... ... open procedures, general instruments, non-drug coated implantables, large endoscopes, needle ... in use over the last two to three decades for ...
Breaking Medicine Technology:
(Date:2/19/2017)... ... ... Braun Industries will be participating as an exhibitor at EMS Today 2017. ... 23-25, 2017 at the Calvin L. Rampton Salt Palace Convention Center in Salt Lake ... on display. , “JEMS is a leader in EMS news and education. ...
(Date:2/19/2017)... ... February 19, 2017 , ... ... in better care, and MEDfx and the Delaware Health Information Network (DHIN) have ... As the nation’s first state-wide health information exchange, DHIN stores and shares real-time ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... Axendia, **FDAnews Free Webinar**, March 1, 2017 — 1:30 p.m. – 2:30 ... regulatory burden? Pay dividends in enhanced and predictable product performance? Streamline processes ...
(Date:2/18/2017)... ... 17, 2017 , ... Butler Mobility invited Ken Matthews to visit its manufacturing ... Ken was impressed with the safety and reliability of the Stannah Stairlift as ... show. This endorsement by Ken Matthews can be heard on News Radio WHP ...
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter ... Show on the Pet Life Radio network. The episode, which was posted this ... topics including: what factors led to Park Cities Pet Sitter’s being awarded the 2017 ...
Breaking Medicine News(10 mins):